The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.
about
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceuticalDetermination of caspase-3 activation fails to predict chemosensitivity in primary acute myeloid leukemia blasts.BAG3 protein controls B-chronic lymphocytic leukaemia cell apoptosisIbrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axisHomozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOPTherapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignanciesOcaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemiaIdentification of cell surface and secreted proteins essential for tumor cell survival using a genetic suppressor element screen.The potential effect of statins on rituximab immunotherapy.Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaPhase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignanciesGenetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab.A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphomaImmunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma.Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes.The clinical application of monoclonal antibodies in chronic lymphocytic leukemia.Antibody therapy for chronic lymphocytic leukemia.EDL-360: A Potential Novel Antiglioma Agent.CD20-mediated apoptosis: signalling through lipid rafts.Rituximab resistance.Caspase-mediated cell death in hematological malignancies: theoretical considerations, methods of assessment, and clinical implications.The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximabRituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.How does B cell depletion therapy work, and how can it be improved?Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL).Apoptosis as a tool for therapeutic agents in haematological diseases.Empowering targeted therapy: lessons from rituximab.Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATPTherapeutic antibodies against cancer.Rituximab for autoimmune haemophilia: a proposed treatment algorithm.Regulators of apoptosis: suitable targets for immune therapy of cancer.Monoclonal antibody therapy of leukaemias and lymphomas.Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: a case study.Development of antibodies for cancer therapy.Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia.Monoclonal antibody-based therapeutics for leukemia.Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas.
P2860
Q24681992-E7E83C9C-EA2D-48CE-B544-E71BA507A82DQ24814114-BCF292C6-4BC0-4376-A6A7-A2BD0974663FQ28191626-A8E1FC72-BCED-4838-826B-1D5287D53DC4Q28277551-D06B211C-FA5C-45A4-8C93-C06DCB88C56BQ28389577-4A1A45D4-F161-44F0-ACB4-3DDA1A725443Q28478591-CCCC1E63-A66B-467B-A09F-6E6F261E55A2Q30577607-FDCB09B1-F718-4DAC-BAA0-F9B7058B82ACQ31111319-F2A2D209-21C4-4D62-8961-2738D4AC788CQ33325581-8F16E7D9-BB13-4FEC-8054-2467CA22903EQ33382030-DD5C794F-9D4A-45BA-8777-C21241A8108CQ33386193-6B1843A1-13C4-484F-9605-181D462DD1A4Q33422543-5C0BC8FA-D51E-4ABB-9F37-E88CB40CF29FQ33556514-29990BC8-6B45-4FCB-830A-4E041FF9E598Q34007430-B53E9A66-32E3-42BA-8352-59A181E5D5C5Q34021592-23F6E919-8C65-4EC2-B8C8-FDD59B1BF7F9Q34097414-6E071C14-CDE2-4FDF-A813-B92E0DA872C6Q34310845-F0328F06-2CC3-4CFB-81D7-4D269A2FB139Q34589909-3C77AD7D-14CE-4522-8EAF-DAC35ACC5373Q34845272-D826CC54-8027-40F8-BDDC-73D0B3C6FF3DQ34969960-C8AF3FD1-48C1-414D-9E82-7BCD4FED7F36Q35041270-A8F5871B-86F5-49FD-BF39-C7C1B2952C6EQ35198905-12389006-34EA-43E0-866F-4E0C2AF3CA44Q35525404-7FD1DCCE-0E76-467E-99D3-39FD30CD81CEQ35567244-E281979F-7D66-4A67-976F-680B0BD9692BQ35569418-05C34E48-075B-4FFC-BF66-A2004CF62DCDQ35579475-DDB6E04A-065F-4381-9F52-F79BC7CD1D02Q35683808-6AA5038E-091E-47CB-89EA-FA304487497AQ35684882-2F4F2D5B-AEAD-43E8-B7BA-F36BC748E227Q35835795-D7399E7F-9037-4301-90FF-811D1BE632ABQ35847611-F622B43B-A320-47DE-841A-0B340DF60631Q35908498-6966F76A-E164-4423-998F-6677AA93F10FQ36014987-3439F715-F045-42DF-86D4-61DAF46B5F62Q36111911-6FF0A8E0-FB57-409D-9651-438282F4D427Q36239669-42E22212-EDE3-47FE-A26B-CB68C7352D7AQ36402809-54298A08-9929-4E52-8758-09BB86CF247DQ36541958-65D7CC84-252A-44C5-B793-338E3205BFB5Q36689156-BD75FAA9-3C29-4176-8FC1-8126B419CBF7Q36739759-B40AA950-2F03-47F4-805F-EAD7EFFD0F30Q36974707-B636FF3B-923C-42FB-8D04-8CF5E130E487Q36981694-4BAA0C9D-0A1F-474E-B294-4D7C60915A82
P2860
The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
The mechanism of tumor cell cl ...... ation and apoptosis induction.
@en
The mechanism of tumor cell cl ...... ation and apoptosis induction.
@nl
type
label
The mechanism of tumor cell cl ...... ation and apoptosis induction.
@en
The mechanism of tumor cell cl ...... ation and apoptosis induction.
@nl
prefLabel
The mechanism of tumor cell cl ...... ation and apoptosis induction.
@en
The mechanism of tumor cell cl ...... ation and apoptosis induction.
@nl
P2093
P356
P1433
P1476
The mechanism of tumor cell cl ...... ation and apoptosis induction.
@en
P2093
David Lucas
Ian W Flinn
Jennifer L Aron
John C Reed
Michael Pearson
Shinichi Kitada
P304
P356
10.1182/BLOOD.V99.3.1038
P407
P50
P577
2002-02-01T00:00:00Z